A. J. Ullmann, J. M. Aguado, S. Arikan-akdagli, D. W. Denning, A. H. Groll et al., Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline, Clin Microbiol Infect, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01953645

A. A. Barg, S. Malkiel, M. Bartuv, G. Greenberg, A. Toren et al., Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients. Pediatr Blood Cancer, 2018.

A. Pomorska, A. Malecka, R. Jaworski, J. Radon-proskura, R. K. Hare et al., Isavuconazole in a successful combination treatment of disseminated mucormycosis in a child with acute lymphoblastic leukaemia and generalized haemochromatosis: a case report and review of the literature, Mycopathologia, 2018.

F. Tissot, S. Agrawal, L. Pagano, G. Petrikkos, A. H. Groll et al., ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

A. H. Groll, E. Castagnola, S. Cesaro, J. H. Dalle, D. Engelhard et al., ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation, Fourth European conference on infections in Leukaemia, 2014.

F. M. Marty, L. Ostrosky-zeichner, O. A. Cornely, K. M. Mullane, J. R. Perfect et al., Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis, Lancet Infect Dis, issue.16, pp.71-73, 2016.

J. A. Maertens, . Raad, . Ii, K. A. Marr, T. F. Patterson et al., Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomisedcontrolled, non-inferiority trial, Lancet, issue.15, pp.1159-1168, 2016.

D. Bitar, D. Van-cauteren, F. Lanternier, E. Dannaoui, C. D. Dromer et al., Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis, 2009.

A. Skiada, L. Pagano, A. Groll, S. Zimmerli, B. Dupont et al., Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on Zygomycosis between, 2005.

, Clin Microbiol Infect, 2011.

G. Petrikkos, A. Skiada, and M. Drogari-apiranthitou, Epidemiology of mucormycosis in Europe, Clin Microbiol Infect, 2014.

F. Lanternier, E. Dannaoui, G. Morizot, C. Elie, D. Garcia-hermoso et al., A global analysis of mucormycosis in France: the RetroZygo study, Clin Infect Dis, 2005.
URL : https://hal.archives-ouvertes.fr/hal-00818503

O. A. Cornely, S. Arikan-akdagli, E. Dannaoui, A. H. Groll, K. Lagrou et al., ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013, Clin Microbiol Infect, 2014.

Z. D. Pana, D. Seidel, A. Skiada, A. H. Groll, G. Petrikkos et al., Collaborators of Zygomyco.net and/or FungiScope R. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries, BMC Infect Dis, 2016.

F. Lanternier, S. Poiree, C. Elie, D. Garcia-hermoso, P. Bakouboula et al., Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis, J Antimicrob Chemother, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02317920

T. Felton, P. F. Troke, and W. W. Hope, Tissue penetration of antifungal agents, Clin Microbiol Rev, 2014.

T. Jancel, P. A. Shaw, C. W. Hallahan, T. Kim, A. F. Freeman et al., Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review, J Clin Pharm Ther, 2016.

M. P. Ledoux, E. Toussaint, J. Denis, and R. Herbrecht, New pharmacological opportunities for the treatment of invasive mould diseases, J Antimicrob Chemother, 2017.

D. Farmakiotis, D. P. Kontoyiannis, and . Mucormycoses, Infect Dis Clin N Am, 2016.